Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization. [electronic resource]
Producer: 20100309Description: 15-22 p. digitalISSN:- 1083-4087
- Antibodies, Monoclonal -- economics
- Antibodies, Monoclonal, Humanized
- Antiviral Agents -- economics
- Cost of Illness
- Cost-Benefit Analysis
- Female
- Health Care Costs
- Hospitalization -- statistics & numerical data
- Humans
- Infant
- Infant, Newborn
- Male
- Managed Care Programs
- Outcome Assessment, Health Care
- Palivizumab
- Pediatrics
- Practice Guidelines as Topic
- Respiratory Syncytial Virus Infections -- economics
- Retrospective Studies
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.